Exploring Microbial Diversity in Pancreatic Diseases
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Road II, Shanghai 200025, China
This study is trying to see if the types of germs found in pancreatic tissue can help us understand different pancreatic diseases, like pancreatic cancer, to improve diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 5 Years to 85 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05193162 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between microbial diversity in pancreatic tissue and various pancreatic diseases, including pancreatic cancer. By analyzing tissue samples from patients operated on between January 2005 and June 2022, the study aims to identify specific microbial flora associated with different pancreatic conditions. High throughput sequencing will be utilized to characterize the microbial communities present in the pancreatic tissues, providing insights into their potential role in disease development and progression. The findings could lead to improved diagnostic and therapeutic strategies for pancreatic diseases.
Who should consider this trial
Good fit: Ideal candidates include patients aged 5 to 85 who have undergone surgery for pancreatic diseases with clear postoperative pathology.
Not a fit: Patients with a history of antibiotic use or probiotics within three months prior to surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance early diagnosis and treatment options for patients with pancreatic diseases.
How similar studies have performed: While studies have explored microbial influences in other diseases, this specific investigation into pancreatic diseases is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 5 years old, ≤ 85 years old; * After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases; * No history of antibiotics for three months before surgery, no history of yogurt containing probiotics * There is no serious damage to heart, liver and kidney function. Exclusion Criteria: * Antibiotics or yogurt containing probiotics history in three months; * Patients with evidence of sensory or motor neuropathy; * Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection; * Those who have a history of other cancers.
Where this trial is running
Shanghai
- Ruijin Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Wei Wang, Dr.
- Email: wangwei_0306@163.com
- Phone: +86- 13761648121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.